Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) Conference call and webcast to discuss data on ...

While RSV affects children and adults, it's particularly dangerous for kids under 1-year-old and seniors 65 years old and older. According to the CDC, there are between 100 to 500 pediatric deaths ...

Today’s readout comes a couple of months after Enanta’s L-protein inhibitor, dubbed EDP-323, scored its own phase 2 win in RSV. That EDP-323 study raised “the high bar set by zelicapavir ...

Up to 80,000 children under age 5 are hospitalized due to RSV every year. A mother is speaking out about how dangerous respiratory syncytial virus, or RSV, can be as her 2-year-old battles the ...

Respiratory syncytial virus The number of Colorado children who didn’t get common viruses in 2020 and 2021 contributed to the massive number of RSV cases in fall 2022.

Short for respiratory syncytial virus, RSV is a common ailment that usually causes mild cold-like symptoms, according to the CDC. Most people recover in a week or two, but the virus can be serious ...

GSK said its RSV vaccines were thoroughly tested for safety and efficacy, proving 82.6% effective against RSV in older adults over one season and 67.2% over the cumulative course of two seasons.

Notably, SARS-CoV-2 is observed to be lower in sensitivity to 4′-FlU as compared to RSV. This could be because of the exonuclease activity of the coronavirus polymerase against 4′-FlU.